Chemically inducible gene switches that regulate expression of endogenous genes have multiple applications for basic gene expression research and gene therapy. Single-chain zinc-finger transcription factors that utilize either estrogen receptor homodimers or retinoid X receptor-a/ecdysone receptor heterodimers are shown here to be effective regulators of ICAM-1 and ErbB-2 transcription. Using activator (VP64) and repressor (Krü ppel-associated box) domains to impart regulatory directionality, ICAM-1 was activated by 4.8-fold and repressed by 81% with the estrogen receptor-inducible transcription factors. ErbB-2 was activated by up to threefold and repressed by 84% with the retinoid X receptor-a/ecdysone receptor-inducible transcription factors. The dynamic range of these proteins was similar to the constitutive system and showed negligible basal regulation when ligand was not present. We have also demonstrated that the regulation imposed by these inducible transcription factors is dose dependent, sustainable for at least 11 days and reversible upon cessation of drug treatment. Importantly, these proteins can be used in conjunction with each other with no detectable overlap of activity enabling concurrent and temporal regulation of multiple genes within the same cell. Thus, these chemically inducible transcription factors are valuable tools for spatiotemporal control of gene expression that should prove valuable for research and gene therapy applications.
Introduction
Artificial zinc-finger transcription factors (TF ZF s) have been used to discover, regulate and study genes in vitro and in vivo.
1,2 Zinc-finger (ZF) domains are modular and can be combined to create new proteins of desired DNAbinding specificity. By taking comprehensive approaches and using phage display selection strategies, we and others have successfully prepared ZF domains that target almost all GNN, ANN and CNN DNA triplets. [3] [4] [5] [6] [7] Typically, designer TF ZF s are composed of up to six ZF domains; a six-finger ZF binds to 18 bp of DNA; this allows recognition of a unique sequence within the human genome. 8 When combined with repressor or activator domains, ZF proteins can be used to regulate transcription of genes. For instance, to regulate the ErbB-2/HER-2 gene, the E2C polydactyl ZF was designed to bind to a specific sequence within the promoter. This ZF domain has been fused to the herpes simplex VP16 transcriptional activation domain (VP64), transcriptional repression domains like the Krü ppel-associated box (KRAB), 9 mad mSIN3 interaction domain 10 and a nuclear localization signal. 11, 12 As an alternative to individual rational design of ZF proteins for each target sequence, high-throughput and genome-wide approaches have been developed to directly isolate functional TF ZF s from large libraries of randomly shuffled ZF domains. 13, 14 Using this type of rapid selection in mammalian cells, a regulator of intercellular adhesion molecule-1 (ICAM-1), CD54-31-TF ZF , was isolated. The TF ZF binds with high affinity and specificity to a unique site of the ICAM-1 promoter. 15 Most TF ZF s have been constructed for constitutive regulation of natural promoters driving reporter genes. 11, 16, 17 TF ZF s have been expressed from constitutive promoters transiently, retrovirally or by generating integrated stable cell lines [18] [19] [20] [21] and have also been expressed in vivo. 22 To effectively study gene function and develop gene therapies, tightly controlled and highly inducible regulation of the target gene is desirable through direct control of the TF ZF with a cell-penetrating drug. Inducible transcription regulatory systems, or gene switches, are chimeric transregulators typically consisting of a DNAbinding domain (DBD) fused to a transcription effector domain (ED) and a ligand-binding domain (LBD). These chimeric transregulators dimerize upon drug addition and eventually undergo conformational changes that result in control of a target promoter ( Figure 1 ). As these systems have been based on naturally existing DBDs of definite DNA sequence specificity, use has been restricted to regulation of exogenously delivered transgenes or reporter genes 23 ( Figure 1a ). Use of ZF-based domains as the DBD of the chimeric transregulator allows targeting of virtually any sequence in a promoter, minimizing endogenous cross-reactivity and potentially allowing regulation of any desired chromosomal promoter. The first ZF-based gene switches were under the control of a tetracycline-or ecdysone-inducible response element. However, this required co-expression of the LBD transregulators and imposed the use of preengineered host cells or the generation of stable cell lines for the regulation of endogenous genes 18, 19, 24 or transgenes 6, 25 ( Figure 1b ). An advance came with the development of systems that fused split TF ZF s with LBDs or dimerizer domains. This is typically achieved by the drug-dependent reconstitution of functional transregulatory heterodimers that connect the DBD to the ED 12, 26 ( Figure 1c ). These systems did not require use of stable cell lines, but did, however, require the delivery and expression of the two separate components, ideally at equimolar concentrations. We previously reported inducible gene switches based on nuclear hormone receptor LBDs and E2C-TF ZF s to demonstrate the upregulation of the ErbB2 promoter by ligand-dependent transcription regulators in transient reporter luciferase assays. 12 Homodimeric single-chain gene switches provide the advantage of requiring delivering of only one expression cassette, but require two identical target sequences at a certain distance and orientation to each other in the promoter (Figure 1d ). More sophisticated versions are monomeric proteins composed of a TF ZF controlled by two linker-associated estrogen receptor LBDs (scER) or by the retinoid X receptor-a linked to the ecdysone receptor (RE) (Figure 1e) .
In this study, we demonstrate endogenous gene regulation by monocistronically encoded single-chain gene switches that avoid the problems inherent to the coexpression of heterodimers or transgenes and alleviate the specific constraints that homodimers place on the nature of the target site. By combining constitutive retroviral expression in bulk cell populations and single-chain gene switches targeting 18 unique base pairs within DNA promoter sequences of endogenous genes, we demonstrated simultaneous positive and 
Results

Constitutive ICAM-1 and ErbB2 endogenous gene regulation
To establish a generic gene switch system for endogenous gene regulation, previously described designer six-ZF proteins were used as DBD models. When fused to VP64 activation or KRAB-repression domains, CD54-31 and E2C regulate the promoters of the ICAM-1 15 and ErbB2 18 genes, respectively, with exquisite specificity. Constitutive expression of the TF ZF s from the pMX retroviral vector in HeLa and A431 cells allowed for the almost complete knockdown and a four-to sixfold overexpression of each gene product in the whole-cell populations; results were quantified using specific antitarget antibodies with either flow cytometry or western blotting ( Figure 2 ).
Inducible regulation of endogenous gene expression by single-chain iTF ZF s gene switches
Because the control of endogenous gene expression with cell permeable drugs is highly desirable, iTF ZF s endogenous gene switches were generated by subcloning the TF ZF s fused with single-chain hormone receptor LBDs into the pMX vector. The N-terminal ZF DBD and the C-terminal transcriptional ED were separated by dimeric hormone-binding domains, consisting of two estrogen receptor LBDs joined by an 18 amino-acid linker (scER) or of the retinoid X receptor-a linked to the ecdysone receptor with an 18 or a 30 residue long peptide (RE and RLE, respectively) ( Figure 1e ). By fusion of the hormone receptor into the TF ZF , the activity of the artificial transcription factors and consequently, the regulated expression of the target genes were rendered druginducible. When expressed transiently, the prototype ligand-dependent transcription factors E2C-scER-VP64, E2C-RE-VP64 and E2C-RLE-VP64 were previously described to upregulate an ErbB2 promoter driving a luciferase reporter gene in presence of 4-hydroxytamoxifen (4-OHT) and ponasterone-A (ponA). 12 All combinations of CD54-31 and E2C six-ZFs, coupled with the scER-, RE-and RLE-inducible domains to the VP64 and KRAB EDs, were cloned into the retroviral pMX vector. The resulting constructs (pMX-CD54-31-scER-VP64, pMX-CD54-31-scER-KRAB, pMX-CD54-31-RE-VP64, pMX-CD54-31-RE-KRAB, pMX-CD54-31-RLE-VP64, pMX-CD54-31-RLE-KRAB, pMX-E2C-scER-VP64, pMX-E2C-scER-KRAB, pMX-E2C-RE-VP64, pMX-E2C-RE-KRAB, pMX-E2C-RLE-VP64 and pMX-E2C-RLE-KRAB) were transiently co-delivered into the 293-GagPol packaging cell line with a plasmid encoding the vesicular stomatitis virus (VSV) pseudotyping viral envelope. The cell supernatants containing the viral particles were applied to HeLa or A431 cells for infection.
Whereas no induction was observed when the mocktransduced cells were treated with 4-OHT or ponA (not shown), retrovirally delivered iTF ZF s efficiently upand downregulated the expression of the chromosomal ICAM-1 and the ErbB2 genes in presence of inducers ( Figure 3) . Notably, the estrogen receptor-based CD54-31 scER iTF ZF s controlled the ICAM-1 gene with virtually no alteration of expression in the absence of drug and with an average of 4.8-fold activation and 81% percent of repression equivalent to or better than the constitutive forms in the presence of drug (compare Figures 3a and b with Figure 2a) . Although the retinoid X/ecdysone receptor gene switches regulated ICAM-1 in HeLa cells less efficiently than the scER iTF ZF s, these iTF ZF s increased ICAM-1 expression up to sixfold in A431 cells in the presence of drug (data not shown). The E2C-RE and E2C-RLE endogenous gene switches controlled the ErbB2 target gene with low basal activity and good inducibility, whereas the E2C-scER switches were ineffective (Figures 3c and d) .
Reversible, sustainable and latent iTF ZF s activity. To investigate the robustness and the reversibility of the inducible activity, cell-surface expression of ICAM-1 was determined in HeLa cells transduced with CD54-31-scER, -RE and -RLE iTF ZF s fused with the VP64 transactivation domain (Figure 4a ). If no drug was applied, ICAM-1 expression was the same as in untransduced cells. When cells were treated with chemical inducer for 2 days and grown for 7 more days in the presence of drug treatment, expression was upregulated. When cells were treated with chemical inducer for 2 days and grown for 7 more days in the absence of drug treatment, expression was initially upregulated and then returned to basal levels without observable changes in cell morphology and proliferation. When transduced cells were grown for 11 days and then drug was added for 2 days, the iTF ZF activity and ICAM-1 upregulation were similar to that observed when drug was added immediately upon infection ( Figure 4b , compare with Figure 3a) . Accordingly, the E2C-RE-VP64 and the E2C-RLE-VP64 iTF ZF s demonstrated a similar robustness in latent inducible activity, regardless of the time of drug addition (that is, after 1 or 11 days post-transduction) ( Figure 4d , compare to Figure 3c ). These experiments demonstrated that, when linked to the VP64 transactivation domain, the scER-, RE-and RLE-based gene switches can be kept in inactive or active states or reversed simply by changing drug content in the cell culture media. ICAM-1 repression in cells expressing CD54-31-KRAB iTF ZF s was almost fully reversible and showed similar repression after 9 days as after 2 days of drug stimulation (data not shown; Figure 3b ). A notable difference was that for the most potent ICAM-1-inducible repressor, CD54-31-scER-KRAB, only a portion (23%) of the bulk-transduced cells were still expressing green fluorescent protein (GFP) and thus exhibiting complete ICAM-1 repression (data not shown). Despite the shortfall of cells expressing IRES-linked GFP over time, CD54-31-scER-KRAB expressing cells were not presenting any ICAM-1 repression after an 11-day period without drug, and after that, were still inducible to reach 60% ICAM-1 repression (Figure 4c ), with the most GFP-positive cells displaying the most ICAM-1 repression (data not shown). to reach a maximal sixfold induction. Downregulation in cells that expressed CD54-31-scER-KRAB was barely measurable at 0.8 nM 4-OHT; at 500 nM 4-OHT, ICAM-1 expression was repressed by 73% and barely detectable by western blot. Although less potent, the retinoid X/ ecdysone receptor-based gene switches were also dosedependent within the range of 100 nM to 5 mM ponA.
Simultaneous and independent inducible co-regulation of ICAM-1 and ErbB2. When the regulation of two endogenous genes is necessary to achieve a complete Endogenous regulation of multiple genes with TF ZF s L Magnenat et al phenotypic or therapeutic effect, it would be valuable to combine two target-specific iTF ZF with dependence on different drugs. This would allow for either activation or repression in a simultaneous or staggered fashion. To demonstrate these possibilities, HeLa cells were cotransduced with the CD54-31 scER iTF ZF and either E2C-RE-KRAB or E2C-RLE-VP64 and then stimulated with 4-OHT and ponA simultaneously ( Figure 6 ). All combinations of ICAM-1 and ErbB2 co-regulations were achieved: Both genes could be chemically repressed or overexpressed, one gene could be downregulated, whereas the other was upregulated, and vice versa. When only one drug was used, only the expected gene was regulated (data not shown). Figure 3 Inducible up-and downregulation of endogenous genes by single-chain inducible zinc-finger transcription factors (iTF ZF s) gene switches containing VP64 transactivator or Krü ppel-associated box (KRAB) repressor domains. HeLa cells retrovirally expressing monomeric intercellular adhesion molecule-1 (ICAM-1) and ErbB2-specific estrogen (scER) and retinoid X/ecdysone receptor with a short or a long linker (RE or RLE respectively) nuclear receptor-based TF ZF s were treated with 4-hydroxytamoxifen (4-OHT) (100 mM) and ponasterone-A (ponA) (5 mM), respectively. Cell-surface expression of target gene products without (dashed black overlay) or after drug induction (thick black overlay) were measured by flow cytometry using specific antibodies and compared to normal protein levels of mock-transduced cells (gray overlay) and cell autofluorescence (dashed gray overlay). 
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Discussion
In this era of genomics and proteomics, the ability to regulate gene expression with the flick of a switch would provide a valuable tool for discovering novel gene function and pathways. A toolbox of chemically inducible gene switches that provide tunable levels of gene expression, which is both sustainable and reversible, would ensure the necessary control needed for basic biological studies, as well as, for gene therapy applications. Previous studies demonstrated that chemically iTF ZF s, prepared using single-chain estrogen receptor homodimers and retinoid X/ecdysone receptor heterodimers with engineered LBDs that are not sensitive to endogenous hormones, worked to regulate transcription of reporter genes in response to bioavailable ligand homologs that are considered safe. 12 Dent et al. 27 used the progesterone receptor in conjunction with a ZF and the p65 activation domain to regulate endogenous VEGF-A. Here we have expanded the gene switch toolbox to show that iTF ZF s prepared using engineered estrogen receptor and retinoid X/ecdysone receptor can both activate and repress the transcription of endogenous genes.
Key features for inducible gene switches include negligible basal regulation, a dynamic range of regulation that approaches the constitutive system, and especially for gene therapy applications, dose-dependent levels of regulation. These features are necessary to ensure tight control of target gene transcription to more closely mimic natural transcriptional control. For ICAM-1 regulation, the scER iTF ZF achieves these goals with 4.8-fold activation, 81% repression and dose dependency over a 1000-fold range of ligand concentration for an overall ICAM-1 expression dynamic range of 25-fold from down-to upregulation (Figures 3-5) . Although the results are not as dramatic for ErbB2 regulation, the RE and RLE receptors show up to threefold activation, 84% repression for a bidirectional induction ratio of 18-fold, and dose dependency over a 50-fold range of ligand concentration (Figures 3-5) The difference observed in the inducible activation of the ICAM-1 and ErbB2 genes with their respective iTF ZF s might reflect different efficacies and mechanisms of action between the scER and RE switches. Different overexpression potential of the two genes with constitutively expressed TF ZF s was also observed. Besides the ErbB2 gene amplification in some tumor cell lines, the position and the affinity of the regulators upstream or downstream of the starts of mRNA transcription, the post-translational limitations in the expression of the respective genes or their different levels of basal expression could possibly result in different inducibility potentials.
Sustainability and reversibility of gene regulation is also important for effective inducible gene switches. Stable, long-term expression of a therapeutic protein or repression of a faulty gene is essential for gene therapy applications and when studying the effects of gene expression in tissue culture or animal models. Consistent gene expression should be able to be maintained for the duration of the treatment, through multiple passages of tissue culture, or through the lifetime of the animal. Full and rapid reversibility and a fine-tuning rheostat of gene regulation is an important safety feature in the event of adverse reactions in gene therapy. For animal models, reversibility would be advantageous for investigating the effects of activating or repressing a gene at a specific stage of development. All of the iTF ZF s showed reversible and sustained activation of ICAM-1 and the RE and RLE iTF ZF s also showed sustained activation for ErbB2. Sustained repression of ICAM-1 was also effective with repression after 9 days of drug stimulation similar to repression after 2 days and 60% drug-inducible repression obtainable after 11 days latency without drug. The observed loss of GFP expression could be caused by retroviral expression silencing or negative selection due to an antiproliferative effect of ICAM-1 repression or iTF ZF expression. 
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In addition, we have shown that the scER and RE iTF ZF s can work in conjunction with each other to independently control endogenous expression of two genes ( Figure 6 ). When both transcription factors and ligands are present, the levels of up-and downregulation of the target genes are equivalent to regulation levels seen when they are used separately. When a single ligand is present, only the target iTF ZF shows gene regulation. This control opens the possibility to regulate transcription of two or more genes simultaneously and independently, which could be useful when studying protein-protein interactions or biological pathways, as well as for experimental approaches in systems biology. When combined with large polydactyl-ZF libraries such as those used recently, 13 iTF ZF inducibility would be an important asset for in vivo screening of new gene modulators at a certain time in living organisms. It could also prove advantageous to treat diseases by repressing transcription of a detrimental protein and activating transcription of a therapeutic protein.
The modularity of the ZFs, nuclear receptor ligandbinding domains and EDs lend themselves to a flexible system in which the parts can be interchanged. Our results show that the efficacy of iTF ZF s varies depending on target promoter and cell line (Figure 3 ). For example in HeLa cells, the scER iTF ZF works very well when targeting the ICAM-1 promoter for both activation and repression, however they were virtually ineffective at regulating ErbB2 expression, whereas the RE-and RLEbased iTF ZF s worked in the opposite manner. The scER may not work with the ErbB2 promoter due to interactions between the estrogen receptor and ErbB2 signaling pathways. Tamoxifen, which in an endogenous ER antagonist, may be affecting AP-2 regulation of ErbB2 transcription. 28 For the RE and RLE iTF ZF s, there is a retinoic acid-responsive element close to the CD54-31- ICAM-1) expression. CD54-31-scER-, -RE-and -RLE inducible zincfinger transcription factors (iTF ZF s) with either -VP64 and -KRAB (Krü ppel-associated box) domains were retrovirally expressed in HeLa cells for 2 days. 4-Hydroxytamoxifen (4-OHT) was added at concentrations ranging from 0.8 to 500 nM or ponasterone-A (ponA) was added at concentrations ranging from 0.05 to 5 mM. ICAM-1 expression was measured on the cell surface by fluorescence-activated cell sorting (FACS) or in cell extracts by western blot (representative of 2-3 independent experiments). (a) Mean fluorescence intensity (MFI) quantification of ICAM-1 activation (normalized to 1 for mock-transduced cells) and repression (normalized to 100) relative to drug dose. (b) Equal total protein amounts of whole-cell extracts were separated on denaturing SDS-polyacrylamide gel electrophoresis (PAGE) with reducing conditions and immunoblotted on polyvinylidene fluoride (PVDF) membranes for the detection of ICAM-1 regulation in comparison to constitutive b-actin expression using specific antibodies. Protein expression levels in cells expressing CD54-31 iTF ZF (-scER-VP64, -scER-KRAB, -RE-VP64 and -RLE-VP64) treated with drug are compared to uninduced mock-transduced cells (HeLa).
Endogenous regulation of multiple genes with TF ZF s L Magnenat et al binding site in the ICAM-1 promoter. [29] [30] [31] [32] Interaction with the retinoic acid receptor that binds here may affect regulation of ICAM-1 expression by the RE and RLE switches. On the other hand, compared to untreated cells, 4-OHT and ponA treatment did not influence the expression of the ErbB2 and ICAM-1 promoters, respectively (compare gray and black overlays in Figure 6 ). We also observed different levels of inducible regulation in A431 cells than in HeLa cells, indicating that CD54-31 iTF ZF s with retinoid X/ecdysone-inducible domains were functionally able to regulate ICAM-1 as well as CD54-31-scER iTF ZF s (data not shown). Cell-type specific and TF ZF -dependent activity has also been seen with constitutive regulators of this type, 15 and thus might reflect differences with endogenous regulators. This variation of regulatory ability demonstrates the need for a variety of ZFs, ligand-inducible receptors and EDs that can be easily assembled in different combinations to optimize performance for the specific application.
Like the system developed by Dent et al., 27 the iTF ZF s presented in this paper are expressed as a single fusion protein enabling simple gene delivery, which is ideal for gene therapy applications. In addition to allowing for inducible repression and using more specific six-fingered DBDs, another advantage of our system is the formation of intramolecular dimers, making dimerization with endogenous nuclear receptors unlikely, although still a possibility when response elements of endogenous nuclear receptors are in close proximity to the iTF ZF target site. The single-chain construction also eliminates the response element repeat requirement of natural nuclear receptors. However, the effect that the ligands and iTF ZF s have on the expression and function of other endogenous genes in various cell and tissue types will have to be studied to identify the iTF ZF with the least potential for side effects.
In conclusion, we have created inducible transcription factors that can activate and repress the expression of endogenous genes. Regulation was shown to be sustainable, reversible, dose dependent, have a dynamic range similar to constitutive regulators, have negligible basal regulation and can be used in conjunction with each other. These iTF ZF s are valuable tools for genomic and proteomic research and gene therapy applications, where spatiotemporal control of gene expression is essential.
Materials and methods
Human cell lines
A431 epidermoid carcinoma cells and HeLa cervix carcinoma cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The 293-GagPol packaging cell line was obtained from I Verma (Salk Institute, San Diego, CA, USA). Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics.
Construction of retroviral plasmids for the expression of iTF ZF s
The expression cassettes of pcDNA E2C monomeric switch constructs, those with C-terminal EDs used in the transient assays, 12 were subcloned into the pMX-IRES-GFP retroviral vector 33 using the following restriction digest and ligation strategy. The single-chain estrogen receptor constructs pcDNA E2C ScER/30-VP64 and -KRAB (30 aa linker) were digested and ligated into pMX E2C-VP64 vector using BamH1-Pac1 restriction enzymes. The single-chain retinoid/ecdysone receptor constructs pcDNA E2C-RE-VP64 and KRAB (18 residue linker), and E2C-RLE-VP64 and -KRAB (30 residue linker) were digested with Fse1-Pac1 and assembled in Endogenous regulation of multiple genes with TF ZF s L Magnenat et al a one-step two-way ligation with a BamH1-Fse1 E2C fragment into the pMX E2C-VP64 vector previously digested with BamH1 and Pac1. The ICAM-1 gene switch constructs were created by replacing the E2C by the CD54-31 six-finger coding DNA using the Sfi1 restriction enzyme.
Retroviral delivery and inducible iTF ZF s assay
Retroviral transductions were performed using 293-GagPol packaging cells and VSV envelope pseudotyping to produce retrovirus as previously described 15 with the following modifications. With constitutive TF ZF s, target gene expression was measured 72 h after the retrovirus was applied to the cells. Unless otherwise stated in the figure legends, the host cells transduced with the inducible iTF ZF s were split in two dishes 24 h after transduction, and while one-half of the cells was kept uninduced to measure the basal activity of the iTF ZF s, the other half was supplemented with 5 mM ponA (Invitrogen, Carlsbad, CA, USA) or 100 nM 4-OHT (Sigma, St Louis, MO, USA) for the induction of the iTF ZF s based on the estrogen and retinoid X/REs, respectively. After 48 h, the cells were harvested for analysis of the target gene expression by FACS or western blotting. Transduction efficiency and iTF ZF s expression was verified by flow cytometry with the percentage of cells indicating GFP fluorescence, which is co-expressed on the same bicistronic transcript as the iTF ZF s. Using these conditions, the bulk (480%) of the A431 or HeLa cells were expressing GFP after 3 days transduction, which persisted up to 19 days (not shown). The pcDNA3.1 vector (Invitrogen) was used as mock transduction control for the determination of the basal target gene expression. The addition of drug inducer to the negative control cell sample did not alter the cell-surface expression of the targets (data not shown).
Flow cytometric analysis of inducible target gene regulation
At day 3 after cell transduction, cell-surface expression of the target genes was measured with anti-ICAM-1 (clone HA58; BD Pharmingen, San Diego, CA, USA) and antiErbB2 (clone FSP77, gift from Nancy E Hynes, Friedrich Miescher Institute, Basel 34 ) monoclonal antibodies at 5 mg ml À1 and with a phycoerythrin-labeled donkey antimouse immunoglobulin Gsecondary antibody (Jackson Immunochemicals, Westgrove, PA, USA) using a flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Comparative analysis of mean fluorescence intensities (MFI) was determined using CELLQuest software (Becton Dickinson, Franklin Lakes, NJ, USA). MFI was corrected for background by subtraction of the autofluorescence of cells incubated with the secondary antibody only and normalized to the expression value of mock-transduced cells.
Western blotting
For measuring protein expression by western blotting, whole-cell extracts were prepared with cell lysis buffer (50 mM Tris HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100) containing 1 Â protease inhibitor cocktail (Roche, Basel, Switzerland). For each sample, the total protein concentration was determined with a Bradford assay (Bio-Rad, Hercules, CA, USA). Equal amounts of protein were separated on reducing 4-12% bis-tris polyacrylamide gels with 2-(N-morpholinolethane sulfonic acid (MES) SDS buffer and transferred to a Hybond-P polyvinylidene fluoride (PVDF) membrane (Amersham, Piscataway, NJ, USA) according to the instructions of the manufacturer (Invitrogen). For normalization with a constitutive protein, membranes were treated in blocking buffer (PBS, 0.1% Tween 20 (Sigma) with 5% blocking agent (Amersham), incubated with anti-b-actin (clone AC-15; Sigma), washed in phosphate-buffered saline tween-20 (PBST) and detected with a secondary antibody conjugated to horseradish peroxidase. For the detection of the target protein and TF ZF , the membranes were stripped in 62.5 mM Tris-HCl (pH 6.8), 2% SDS and 100 mM b-mercaptoethanol for 30 min at 65 1C, washed in PBST and treated with blocking buffer containing 10 mg ml À1 extravidin and 1 mg ml À1 a-biotin (both Sigma). ICAM-1 was immunostained with a biotinylated anti-ICAM-1 (BAF720; R&D Systems, Minneapolis, MN, USA) and TF ZF proteins with biotinylated anti-influenza hemagglutinin tag (clone 3F10; Roche), respectively. Membranes were then washed and incubated with streptavidin conjugated to horseradish peroxidase (Amersham) in PBST. Alternatively, for the western blots of the dose-response experiments, the anti-ICAM-1 primary antibody was detected with a peroxidasecoupled donkey anti-sheep secondary antibody (Jackson Immunochemicals). The blots were revealed with the ECL Plus kit according to the manufacturer's instructions (Amersham) and exposed to an X-OMAT film (Kodak) or quantified using a Storm 860 phosphorimager (Molecular Dynamics) using the blue chemifluorescence scanning mode. The intensity of the bands corresponding to the respective size of the proteins on reducing gel was quantified using the ImageQuant software (Molecular Dynamics). Endogenous regulation of multiple genes with TF ZF s L Magnenat et al
